Loading...
OTCM
AVXT
Market cap6kUSD
Jul 28, Last price  
0.00USD
Jan 2017
-99.77%
Name

AVAX Technologies Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
Net income
CFO

Profile

AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company's product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.
IPO date
Dec 19, 1996
Employees
Domiciled in
US
Incorporated in
US

Valuation

No data to show